Home » Headlines » Currently Reading:

Morning Headlines 8/7/13

August 6, 2013 Headlines No Comments

Farzad Mostashari, M.D., ONC Chief, Stepping Down

Farzad Mostashari, MD will step down this fall after serving two years as the National Coordinator for Health Information Technology.

Reduction in federal funding will result in job cuts at many Vermont hospitals

Fletcher Allen Health Care (VT) will add 280 jobs over the next 10 years despite an expected $200 million operational loss. The job growth is attributed to its recently implemented Epic system.

Nuance cuts forecast on delayed deals, move to subscription

Nuance lowers its year-end forecast from $1.33 to $1.45 EPS to a revised $1.27 to $1.35 EPS, due largely to contract delays from mobile customers and a migration to a subscription-based revenue model. The news led to a six percent drop in stock price during after hours trading.

View/Print Text Only View/Print Text Only


HIStalk Featured Sponsors

     







Subscribe to Updates

Search


Loading

Text Ads


Report News and Rumors

No title

Anonymous online form
E-mail
Rumor line: 801.HIT.NEWS

Tweets

Archives

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reader Comments

  • Just a Reader: Continuing the blockchain conversation that @DrM and @dysF(n) started on this comments page... I understand how block...
  • HIT Girl: I think I'm going to start applying for random C-level positions now. I won't even bother to read the job description, ...
  • Really???: Getting very Alice-In-Wonderland-y in Trumpville methinks....
  • Epic Employee: Self-scheduling is definitly out there. I personally schedule all my primary care visits through MyChart either on the w...
  • ex-HHC: re:GIFT trial and Coumadin dosing. Medicare wouldn't pay for warfarin-based genotyping and this trial doesnt really seem...

Sponsor Quick Links